Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B

Alexandros Michailidis/iStock Editorial via Getty Images
Pfizer (PFE) on Wednesday announced an exclusive licensing agreement with China-based RNA medicines company Starna Therapeutics to develop and commercialize chimeric antigen receptor T-cell (CAR-T) therapies as part of a deal worth up to $2.6B.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.